HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials.

AbstractBACKGROUND:
Patent foramen ovale closure represents a potential secondary prevention strategy for cryptogenic stroke, but available trials have varied by size, device studied, and follow-up.
METHODS:
We conducted a systematic search of published randomized clinical trials evaluating patent foramen ovale closure versus medical therapy in patients with recent stroke or transient ischemic attack using PubMED, EMBASE, and Cochrane through September 2017. Weighting was by random effects models.
RESULTS:
Of 480 studies screened, we included 5 randomized clinical trials in the meta-analysis in which 3440 patients were randomized to patent foramen ovale closure (n = 1829) or medical therapy (n = 1611) and followed for an average of 2.0 to 5.9 years. Index stroke/transient ischemic attack occurred within 6 to 9 months of randomization. The primary end point was composite stroke/transient ischemic attack and death (in 3 trials) or stroke alone (in 2 trials). Patent foramen ovale closure reduced the primary end point (0.70 vs 1.48 events per 100 patient-years; risk ratio [RR], 0.52 [0.29-0.91]; I2 = 55.0%) and stroke/transient ischemic attack (1.04 vs 2.00 events per 100 patient-years; RR, 0.55 [0.37-0.82]; I2 = 42.2%) with modest heterogeneity compared with medical therapy. Procedural bleeding was not different between study arms (1.8% vs 1.8%; RR, 0.94 [0.49-1.83]; I2 = 29.2%), but new-onset atrial fibrillation/flutter was increased with patent foramen ovale closure (6.6% vs 0.7%; RR, 4.69 [2.17-10.12]; I2 = 29.3%).
CONCLUSIONS:
In patients with recent cryptogenic stroke, patent foramen ovale closure reduces recurrent stroke/transient ischemic attack compared with medical therapy, but is associated with a higher risk of new-onset atrial fibrillation/flutter.
AuthorsMuthiah Vaduganathan, Arman Qamar, Ankur Gupta, Navkaranbir Bajaj, Harsh B Golwala, Ambarish Pandey, Deepak L Bhatt
JournalThe American journal of medicine (Am J Med) Vol. 131 Issue 5 Pg. 575-577 (05 2018) ISSN: 1555-7162 [Electronic] United States
PMID29229471 (Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, Systematic Review)
CopyrightCopyright © 2018 Elsevier Inc. All rights reserved.
Chemical References
  • Anticoagulants
  • Platelet Aggregation Inhibitors
Topics
  • Anticoagulants (therapeutic use)
  • Atrial Fibrillation (etiology)
  • Atrial Flutter (etiology)
  • Foramen Ovale, Patent (surgery)
  • Humans
  • Ischemic Attack, Transient (prevention & control)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Postoperative Complications
  • Randomized Controlled Trials as Topic
  • Secondary Prevention
  • Stroke (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: